CTOs on the Move

Erytech

www.erytech.com

 
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.erytech.com
  • 1 Main Street Suite 300
    Cambridge, MA USA 02142
  • Phone: 857.706.1585

Executives

Name Title Contact Details
Stewart Craig
 Chief Technology Officer Profile
Stewart Craig
 Chief Technology Officer Profile

Similar Companies

Taro Pharmaceutical Industries

Taro Pharmaceutical Industries is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AQP - Affordable Quality Pharmaceuticals

AQP - Affordable Quality Pharmaceuticals, Inc. is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pion

Optimizing drug development with innovative instruments & scientific expertise.

Ionwerks

Ionwerks is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CSL Behring

Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want. For a century, CSL Behring has earned a reputation as a passionate yet responsible organization, driven to care for patients and deliver on its commitments.